Cooper Clark, DO
Ophthalmology · McAllen, TXNPI 1255598488
Payments from drug & device makers
Across 136 payments — averaging $96.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$11K
- Notal Vision, Inc.$411
- Regeneron Healthcare Solutions, Inc.$386
- Genentech USA, Inc.$375
- Alimera Sciences, Inc.$277
- Alcon$250
- plus $798 from 9 others
What the payments were for
- Consulting fees$8,77567%
- Speaking & faculty fees$4113%
- Travel & lodging$8206%
- Food & beverage$3,17824%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 64 | $10,686 |
| Notal Vision, Inc. | 1 | $411 |
| Regeneron Healthcare Solutions, Inc. | 15 | $386 |
| Genentech USA, Inc. | 17 | $375 |
| Alimera Sciences, Inc. | 10 | $277 |
| Alcon | 2 | $250 |
| Astellas Pharma US Inc | 9 | $205 |
| Rxsight Inc | 1 | $144 |
| Novartis | 2 | $138 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $133 |
| Apellis Pharmaceuticals, Inc. | 2 | $51 |
| Sun Pharmaceutical Industries Inc. | 2 | $41 |
| ANI Pharmaceuticals, Inc. | 1 | $33 |
| Bausch & Lomb Americas Inc. | 2 | $31 |
| Biogen | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OZURDEX$9,542
- Clareon$146
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$144
- BEOVU$125
- DURYSTA$116
- Iluvien$112
- Constellation$103
How this compares
$13,183 in reported general payments places this provider in the 80th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketorolac Tromethamine | 83 | $3,609 |
| Prednisolone Acetate | 27 | $1,570 |
| Ofloxacin | 33 | $399 |
| ErythromycinErythromycin Base | 15 | $159 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in McAllen
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Patrick WilliamsArlington$6.6M
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
- Michael SingerSan Antonio$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.